How are rheumatology professionals affected by the physical distancing and other challenges presented by COVID-19? The Rheumatologist interviewed Adena Batterman, MSW, LCSW, senior manager of inflammatory arthritis support and education programs at the Hospital for Special Surgery, New York, to discuss how the pandemic has changed the way she and her staff maintain continuity of…
New Processes May Stick Around After the Pandemic: Q&A with Wendy Ramey, BSPharm, RPh, CSP
How are COVID-19 and physical distancing restrictions at work affecting rheumatology professionals? The Rheumatologist interviewed clinical pharmacist Wendy Ramey, BSPharm, RPh, CSP, to discuss how the pandemic has changed the way her staff supports rheumatologists at the University of Kentucky Specialty Pharmacy and Infusion Services, Lexington. Ms. Ramey describes how these unprecedented times affect patients,…
Industrial Fine Particulate Air Pollution Linked to Increased ACPA Positivity
Researchers investigating the effects of air pollutants on a biomarker for rheumatic autoimmune diseases have found a significant correlation between anti-citrullinated protein antibody positivity in the general population and exposure to industrial fine particulate matter…
How to Leverage Patient-Reported Outcomes to Improve Care for SLE Patients
A recent study reinforces the growing understanding that the fatigue many SLE patients experience should be considered a lupus symptom. Researchers found that using patient-reported outcomes to identify type 2 symptoms of SLE may improve patient communication, understanding and overall care…
Data on Arthritis Drug to Treat Coronavirus Could Come within Weeks
(Reuters)—Initial data from clinical trials testing whether patients with severe coronavirus illness can be helped by a rheumatoid arthritis drug sold by Regeneron Pharmaceuticals Inc and Sanofi SA may come as early as next week, Regeneron’s chief scientific officer told Reuters. “We could be one to two weeks—at most a month or so—away from knowing…
Amneal Running Out of HCQ Raw Material Due to Finnish Restrictions
NEW YORK/HELSINKI (Reuters)—Amneal Pharmaceuticals could soon run out of the raw ingredients to make more of the anti-malarial drug hydroxychloroquine (HCQ) that has been touted as a potential treatment for COVID-19 because Finland is keeping the drug for domestic use, according to the generic drugmaker’s chief executives. Amneal has committed to producing about 20 million…
Cortisone Shots Less Effective Than PT for Arthritis-Related Knee Pain
(Reuters Health)—People with stiff and aching knees due to arthritis get better relief from physical therapy than from cortisone injections, according to a one-year military study comparing the two treatments. A multi-disciplinary team of doctors reports in The New England Journal of Medicine that people who initially scored 107 on a 241-point scale measuring a…
A Transition to 90% Telemedicine: Q&A with Karim Masri, MD
How are COVID-19 and current restrictions on physical distancing affecting rheumatologists? The Rheumatologist interviewed Karim Masri, MD, to ask how the pandemic has changed the way he and his clinic staff deliver patient care, and how these unprecedented times affect patients, staff and life outside the office. Dr. Masri is a practicing rheumatologist at Bon…
FDA Accelerates Approvals of Generic Versions of HCQ
On April 7, the FDA approved an Abbreviated New Drug Application (ANDA) for Hydroxychloroquine Sulfate Tablets USP, 200 mg, for the treatment of: 1) uncomplicated malaria due to P. falciparum, P. malariae, P. ovale and P. vivax; 2) chronic discoid lupus erythematosus and systemic lupus erythematosus in adults; and 3) treatment of acute and chronic…
Tocilizumab Begins Clinical Trial for COVID-19
The FDA has authorized a phase 3 clinical trial examining the safety and efficacy of tocilizumab plus standard care in patients hospitalized with COVID-19…
- « Previous Page
- 1
- …
- 83
- 84
- 85
- 86
- 87
- …
- 309
- Next Page »